{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["58(10)"],"submitter":["Manning J"],"pubmed_abstract":["Dihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered as a monthly 3-day regimen. We sought to evaluate the protective efficacy of a compressed monthly 2-day treatment course in the Royal Cambodian Armed Forces. The safety and efficacy of a monthly 2-day dosing regimen of dihydroartemisinin-piperaquine were evaluated in a two-arm, randomized, double-blind, placebo-controlled cohort study with 2:1 treatment allocation. Healthy military volunteers in areas along the Thai-Cambodian border where there is a high risk of malaria were administered two consecutive daily doses of 180 mg dihydroartemisinin and 1,440 mg p"],"journal":["Antimicrobial agents and chemotherapy"],"pagination":["6056-67"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4187937"],"repository":["biostudies-literature"],"pubmed_title":["Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval."],"pmcid":["PMC4187937"],"pubmed_authors":["Sriwichai S","Lanteri C","Chour CM","Vanachayangkul P","Tang D","Se Y","Prom S","So M","Siripokasupkul R","Sea D","Saunders D","Soh E","Teja-Isavadharm P","Manning J","Kaewkungwal J","Somethy S","Spring M","Cantilena L","Chann S","Lon C","Mitprasat M","Kuntawunginn W","Phann ST","Auayporn M","Buathong N","Haigney M","Timmermans A"],"additional_accession":[]},"is_claimable":false,"name":"Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.","description":"Dihydroartemisinin-piperaquine, the current first-line drug for uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in Cambodia, was previously shown to be of benefit as malaria chemoprophylaxis when administered as a monthly 3-day regimen. We sought to evaluate the protective efficacy of a compressed monthly 2-day treatment course in the Royal Cambodian Armed Forces. The safety and efficacy of a monthly 2-day dosing regimen of dihydroartemisinin-piperaquine were evaluated in a two-arm, randomized, double-blind, placebo-controlled cohort study with 2:1 treatment allocation. Healthy military volunteers in areas along the Thai-Cambodian border where there is a high risk of malaria were administered two consecutive daily doses of 180 mg dihydroartemisinin and 1,440 mg p","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Oct","modification":"2026-04-29T19:37:53.872Z","creation":"2019-03-26T23:50:36Z"},"accession":"S-EPMC4187937","cross_references":{"pubmed":["25092702"],"doi":["10.1128/aac.02667-14","10.1128/AAC.02667-14"]}}